Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal supplement fails to show clear benefit in optic neuritis pilot

NCT ID NCT02976766

Disease control Sponsor: First Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested whether adding gypenosides (a herbal supplement) to standard steroid treatment could help protect the nerve at the back of the eye in adults having their first episode of acute optic neuritis. Ten participants were enrolled, but the study was stopped early. The main goal was to measure nerve thickness in the affected eye after six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

10 people

The number who actually took part.

Started

Feb 2017

Finished

Jul 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria 1. Male and female Chinese patients aged ≥18 to ≤60 years 2. Patients with a first episode of optic neuritis in the eye of interest 3. First symptoms of optic neuritis ≤28 days prior to the first administration of investigational product 4. Best corrected visual acuity in the eye of interest ≤0.8 Exclusion criteria 1. Pre-existing multiple sclerosis MS or NMO 2. Refractive media opacity 3. Hyperopia \>5 diopters, myopia \<-5 diopters, or astigmatism \>3 diopters 4. Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with HIV or syphilis, or any other conditions potentially interfering treatment trial 5. Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc) 6. Existing other retina or optic nerve diseases 7. Pregnant or females who plan to be pregnant during study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Optic neuritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

optic neuritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Optic neuritis

Contacts and locations

Locations

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.